All In Biotech

Drug Trial Radar · NCT04442490

A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of SAGE-217 in the Treatment of Adult Subjects With Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: Dec 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 543 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

543

Actual

Start

May 12, 2020

Primary completion

Mar 26, 2021

Study completion Apr 21, 2021

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Jun 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study to evaluate the efficacy of SAGE-217 in the treatment of participants with MDD.

Conditions

  • Depressive Disorder, Major

Interventions

  • SAGE-217Drug

    SAGE-217 oral capsules.

  • PlaceboDrug

    SAGE-217 matched-placebo oral capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the 17-item HAM-D Total Score at Day 15Time frame: Baseline, Day 15

Locations

39 sites in 1 country. Site status is shown where the registry gives one.

  • Sage Investigational Site

    Rogers, Arkansas

  • Sage Investigational Site

    Bellflower, California

  • Sage Investigational Site

    Garden Grove, California

  • Sage Investigational Site

    Glendale, California

  • Sage Investigational Site

    Lemon Grove, California

  • Sage Investigational Site

    Orange, California

  • Sage Investigational Site

    Pico Rivera, California

  • Sage Investigational Site

    Redlands, California

  • Sage Investigational Site

    San Diego, California

  • Sage Investigational Site

    Sherman Oaks, California

  • Sage Investigational Site

    Temecula, California

  • Sage Investigational Site

    Coral Springs, Florida

  • Sage Investigational Site

    Hollywood, Florida

  • Sage Investigational Site

    Jacksonville, Florida

  • Sage Investigational Site

    Lauderhill, Florida

  • Sage Investigational Site

    Orange City, Florida

  • Sage Investigational Site

    Orlando, Florida

  • Sage Investigational Site

    Orlando, Florida

  • Sage Investigational Site

    Alpharetta, Georgia

  • Sage Investigational Site

    Atlanta, Georgia

  • Sage Investigational Site

    Atlanta, Georgia

  • Sage Investigational Site

    Decatur, Georgia

  • Sage Investigational Site

    Skokie, Illinois

  • Sage Investigational Site

    Flowood, Mississippi

  • Sage Investigational Site

    O'Fallon, Missouri

  • Sage Investigational Site

    Las Vegas, Nevada

  • Sage Investigational Site

    Marlton, New Jersey

  • Sage Investigational Site

    Charlotte, North Carolina

  • Sage Investigational Site

    Cincinnati, Ohio

  • Sage Investigational Site

    Dayton, Ohio

  • Sage Investigational Site

    North Canton, Ohio

  • Sage Investigational Site

    Oklahoma City, Oklahoma

  • Sage Investigational Site

    Portland, Oregon

  • Sage Investigational Site

    Allentown, Pennsylvania

  • Sage Investigational Site

    Charleston, South Carolina

  • Sage Investigational Site

    Memphis, Tennessee

  • Sage Investigational Site

    DeSoto, Texas

  • Sage Investigational Site

    Wichita Falls, Texas

  • Sage Investigational Site

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.